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P R E V I E W SAPPLied mechanics: Uncovering how adiponectin
modulates insulin action
Adiponectin, an adipocyte secretory hormone, has been causally linked to insulin resistance in the metabolic syndrome
and diabetes. A recent paper (Mao et al., 2006) shows that the APPL1 adaptor protein binds to the intracellular domain of
adiponectin receptors and mediates some of adiponectin’s actions, identifying a novel mechanism linking adiponectin to
insulin sensitization.Adipose tissue is the largest endocrine
organ in the body, secreting biologically
active hormones or ‘‘adipokines’’ that
participate in the regulation of metabo-
lism. The adipokine termed adiponectin,
or Acrp30/AdipoQ, was first identified in
1995 (Scherer et al., 1995) and has since
been shown to ameliorate insulin resis-
tance, dyslipidemia, atherosclerosis, and
inflammation. Although adiponectin is
presently considered a promising thera-
peutic target, little is known about the
molecular mechanisms by which adipo-
nectin signals within cells. Recent work
(Mao et al., 2006) further advances our
understanding of adiponectin signaling
by focusing on the interaction of the
adiponectin receptor with the APPL1
(Adaptor protein containing pleckstrin
homology domain, phosphotyrosine do-
main, and leucine zipper motif) adaptor
protein.
Adiponectin, a 30 kDa protein secreted
exclusively by adipocytes, aggregates in
a range of forms, from low (trimer and
hexamer) to high (12–18mer) molecular
weight. In human plasma, the full-length
adiponectin protein predominates. How-
ever, proteolytic cleavage of the full-
length protein at amino acid 110 gener-
ates a carboxyl-terminal globular domain
(137 aa), which circulates in low abun-
dance (Kadowaki and Yamauchi, 2005).
Circulating levels of adiponectin are
significantly reduced in mice and hu-
mans with obesity, atherosclerosis, insu-
lin resistance, and type 2 diabetes. In vivo
studies report direct insulin sensitizing
effects for both full-length and globular
adiponectin, which improve insulin resis-
tance and hyperglycemia when adminis-
tered in several murine models of obesity
and diabetes. Adiponectin stimulates
AMPK (AMP-activated protein kinase)
and ACC (acetyl coenzyme-A carboxyl-
ase) phosphorylation in skeletal muscle
and liver, activating glucose transport
and lipid oxidation in muscle and inhi-
biting gluconeogenesis in liver. In addi-CELL METABOLISM : JULY 2006tion, adiponectin increases expression
of PPARa and its target genes, result-
ing in reduced liver and muscle triglycer-
ide content. Interestingly, PPARg ago-
nists such as thiazolidenediones (TZDs)
directly stimulate adiponectin secretion
from adipocytes. TZD-mediated im-
provement in insulin sensitivity correlates
with increased abundance of high
molecular weight forms of adiponectin
in both mice and humans, suggesting
that adiponectin may mediate some of
TZDs’ beneficial effects (Pajvani et al.,
2004).
Two seven-transmembrane-domain
adiponectin receptors, designated
AdipoR1 and AdipoR2, share 67% amino
acid homology. Unlike G protein-coupled
receptors, their C terminus is extracellu-
lar, while their N terminus is intracellular
and does not couple with any known G
protein. AdipoR1 binds with high affinity
to globular adiponectin, while AdipoR2
binds to both full-length and globular adi-
ponectin forms. In mice, AdipoR1 is ubiq-
uitously expressed but is most abundant
in skeletal muscle, while AdipoR2 is pri-
marily expressed in the liver. In contrast,
both receptors are highly expressed in
muscle and liver tissues of rats and hu-
mans (Satoh et al., 2005; Staiger et al.,
2004), suggesting that the full-length
versus globular forms exert differential
effects in each species.
Work by Mao and colleagues now
identifies the first AdipoR1/R2 interacting
protein, APPL1. APPL1, a 70 amino acid
protein, contains several protein interac-
tion domains including a pleckstrin ho-
mology domain, phosphotyrosine (PTB)
binding motif and BAR (Bin-Amphysin-
Rvs)-domain. The authors demonstrate
direct binding of the APPL1 PTB domain
with the AdipoR1 intercellular region, al-
though interestingly, this interaction does
not appear to require tyrosine phosphor-
ylation of the AdipoR1 receptor. Previous
studies have described the interactions
of APPL1 with various proteins, includ-ing Akt2, PI(3)K p110a (Mitsuuchi et al.,
1999), follicle-stimulating hormone re-
ceptor (Nechamen et al., 2004), andro-
gen receptor (Yang et al., 2003) and
DCC (Deleted-in-colon-cancer) protein
(Liu et al., 2002), defining a role for
APPL1 in apoptosis/cell survival/cell
proliferation signaling pathways.
Mao et al. propose a novel function for
APPL1, hypothesizing that APPL1 medi-
ates adiponectin signaling and its effects
on metabolism and insulin sensitivity
(Figure 1). The authors first confirm the
expression of APPL1 in insulin-sensitive
tissues that also express adiponectin re-
ceptors, including liver, skeletal muscle
and adipose, and show that adiponectin
stimulates the association of endoge-
nous APPL1 with AdipoR1. Consistent
with their hypothesis, in cultured myo-
tubes, APPL1 knockdown lowers adipo-
nectin-stimulated fatty acid oxidation,
glucose uptake, and phosphorylation of
AMPK, ACC and p38. Likewise, overex-
pression of wild-type APPL1 enhances
basal GLUT4 translocation, while over-
expression of dominant negative APPL1
inhibits basal, insulin- and adiponectin-
stimulated GLUT4 translocation. The
adiponectin-APPL1 interaction is then
linked to glucose transport by Rab5, a
known APPL1-interacting protein and a
member of a small GTPase family known
to facilitate GLUT4 translocation in cul-
tured adipocytes (Huang et al., 2001).
Overexpression of wild-type Rab5
increases GLUT4 translocation and ex-
pression of an inactive Rab5 mutant de-
creases adiponectin-dependent trans-
location. Finally, the data implicate APPL1
in insulin signaling and adiponectin-
mediated insulin sensitivity. Decreased
APPL1 expression reduces insulin-de-
pendent Akt activation. Moreover, while
adiponectin treatment itself does not af-
fect Akt phosphorylation, co-treatment
of myotubes with both adiponectin and
insulin leads to a synergistic increase in
Akt phosphorylation. This synergism is5
P R E V I E W SFigure 1. Role of APPL1 in adiponectin and insulin signaling in L6 and C2C12 myocytes
APPL1 binds AdipoR1/R2 and is involved in adiponectin-dependent phosphorylation of AMPK and p38,
GLUT4 translocation, glucose uptake, and fatty acid oxidation. Its interaction partner Rab5 is important for
p38 phosphorylation and GLUT4 translocation. APPL1 may also mediate a portion of Akt phosphorylation
through an unknown mechanism.not observed in APPL1 knockdown
cells. These intriguing data suggest that
APPL1 functions in both adiponectin
and insulin signaling pathways and may
be an important mediator of adiponectin-
dependent insulin sensitization in skele-
tal muscle.
This study opens doors to exciting av-
enues of investigation in adiponectin sig-
naling systems. For example, is APPL1
required for all known downstream sig-
naling effects elicited by adiponectin
through AdipoR1/R2, or are there other
as yet unidentified AdipoR1/AdipoR2
binding partners? Furthermore, the pres-
ence of multiple protein interaction do-
mains on APPL1 suggests that APPL1
may associate with a range of other pro-
teins. Importantly, does APPL1 function
in insulin signaling pathways, indepen-
dent of adiponectin action? Results
from Mao et al. (2006) support this hy-
pothesis, but additional studies on this
question are clearly warranted. Addition-
ally, does APPL1 participate in mediating
the insulin-sensitizing effects of the thia-
zolidenediones?
A current paradigm in the development
of insulin resistance involves the role of
chronic activation of the proinflammatory
pathway in insulin target tissues. Recent6data point to the macrophage as a candi-
date initiator cell which can infiltrate adi-
pose tissue, muscle, and perhaps liver
(Kupffer cells) to induce inflammatory
responses. Other data indicate that adi-
ponectin may protect against insulin re-
sistance via its anti-inflammatory effects.
Specifically, adiponectin inhibits TNFa-
mediated inflammation in endothelial
cells, reduces NF-kB signaling in adipose
tissue and macrophages (Yamaguchi
et al., 2005), and stimulates secretion
of anti-inflammatory cytokines such as
IL-10 in monocytes and macrophages.
However, the underlying signaling
mechanisms remain poorly defined.
Integrating APPL1 signaling, inflam-
mation and insulin action will be an im-
portant step, not only in defining the
molecular events that control metabo-
lism, but in decoding the boundaries be-
tween these seemingly divergent signal-
ing systems.
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